DarioHealth financials
$6.62−1.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.6M | $5.2M | $5.0M | $5.4M | $6.8M | $7.6M | $7.4M | $6.3M | $5.8M | $3.6M | $3.5M |
| Gross profit | $3.2M | $3.2M | $2.8M | $3.0M | $3.0M | $3.9M | $4.2M | $3.9M | $2.8M | $2.4M | $132.0K | $610.0K |
| Gross margin | 61.7% | 57.3% | 53.6% | 60.2% | 55.2% | 57.5% | 55.3% | 52.2% | 44.1% | 42.2% | 3.7% | 17.3% |
| Operating income | -$6.5M | -$7.3M | -$8.6M | -$9.5M | -$9.2M | -$9.4M | -$11.7M | -$12.0M | -$16.2M | -$17.9M | -$14.2M | -$15.5M |
| Net income | -$7.9M | $8.25B | -$16.1M | -$9.3M | -$8.8M | $6.79B | -$9.8M | -$9.9M | -$3.4M | -$6.92B | -$12.0M | -$14.2M |
| Net margin | −153.1% | 147723.1% | −307.9% | −185.3% | −163.5% | 100632.0% | −128.8% | −133.6% | −53.9% | −120134.4% | −331.9% | −403.5% |
| Diluted EPS | $-0.85 | $1.25 | — | $-2.96 | $-3.54 | $2.87 | — | $-4.91 | $-1.60 | $-4.00 | $-8.30 | $-9.80 |
| EBITDA | -$6.0M | -$6.8M | -$8.0M | -$8.9M | -$8.4M | -$8.2M | -$9.5M | -$9.9M | -$14.4M | -$16.5M | -$12.9M | -$14.3M |
| Operating cash flow | -$6.1M | -$6.0M | -$5.9M | -$7.3M | -$6.0M | -$6.7M | -$6.7M | -$7.4M | -$11.4M | -$13.1M | -$7.3M | -$8.6M |
| Free cash flow | -$6.1M | -$6.1M | -$5.9M | -$7.4M | -$6.1M | -$6.7M | -$6.8M | -$7.4M | -$11.4M | -$13.2M | -$7.4M | -$8.9M |
| Diluted shares | 9.3M | 6,582.3M | — | 3.1M | 2.5M | 2,368.5M | — | 2.0M | 2.0M | 1,722.1M | 1.4M | 1.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.6M | $15.0M | $21.8M | $31.9M | $22.0M | $27.9M |
| Short-term investments | $7.3M | $5.0M | $4.2M | $0.00 | $0.00 | $0.00 |
| Total debt | $31.1M | $30.9M | $30.7M | $30.6M | $30.5M | $29.2M |
| Total assets | $96.6M | $103.3M | $110.1M | $117.7M | $108.3M | $115.6M |
| Total liabilities | $41.5M | $40.9M | $42.2M | $42.8M | $44.3M | $41.9M |
| Shareholders' equity | $55.1M | $62.4M | $67.9M | $74.9M | $64.0M | $73.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology